
Docket No.: PF-0527-1 DIV



- a) an amino acid sequence of SEQ ID NO:1,
- b) an amino acid sequence of SEQ ID NO:2
- c) a fragment of the amino acid sequence of SEQ ID NO:1 comprising at least 15 amino acids, wherein said fragment binds specifically with an anti-PGAMP-1 antibody,
- d) a fragment of the amino acid sequence of SEQ ID NO:1 comprising at least 15 amino acids, wherein said fragment binds specifically with an anti-PGAMP-1 antibody
- [, c) a naturally-occurring amino acid sequence having at least 90% sequence identity to the sequence of SEQ ID NO:1,
- d) a naturally-occurring amino acid sequence having at least 90% sequence identity to the sequence of SEQ ID NO:2,
 - e) a biologically-active fragment of the amino acid sequence of SEQ ID NO:1,
 - f) an antigenically-active fragment of the amino acid sequence of SEQ ID NO:1,
 - g) a biologically-active/fragment of the amino acid sequence of SEQ ID NO:2, and
 - h) an antigenically-active fragment of the amino acid sequence of SEQ ID NO:2].
- 2. (Twice Amended.) A <u>purified</u> polypeptide [of claim 1] selected from the group consisting of:
 - (a) a polypeptide having at least 90% amino acid sequence identity to SEQ ID NO:1 that binds specifically with an anti-PGAMP-1 antibody [retains at least one functional characteristic of the polypeptide of SEQ ID NO:1], and
 - (b) a polypeptide having at least 90% amino acid sequence identity to SEQ ID NO:2 that binds specifically with an anti-PGAMP-2 antibody [and which retains at least one functional characteristic of the polypeptide of SEQ ID NO:2].
 - 14. (Reiterated) A purified antibody which specifically binds to a polypeptide of claim 1.
 - 15. (Reiterated) A purified agonist which specifically binds to and modulates the activity



mb,

Docket No.: PF-0527-1 DIV

of a polypeptide of claim 1.

16. (Reiterated) A purified antagonist which specifically binds to and modulates the activity of a polypeptide of claim 1.

- 17. (Reiterated) A method for treating or preventing a neoplastic disorder, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 16.
- 18. (Reiterated) A method for treating or preventing a reproductive disorder, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 16.
- 21. (Reiterated) A polypeptide of claim 1, having the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.



22. (Once Amended) A [pharmaceutical] composition comprising a polypeptide of claim 21 in conjunction with a suitable pharmaceutical carrier.

- 23. (Reiterated) An isolated polynucleotide selected from the group consisting of:
- a) a polynucleotide sequence of SEQ ID NO:3
- b) a polynucleotide sequence of SEQ ID NO:4,
- c) a naturally-occurring polynucleotide sequence having at least 90% sequence identity to the sequence of SEQ ID NO:3,
- d) a naturally-occurring polynucleotide sequence having at least 90% sequence identity to the sequence of SEQ ID NO:4 and
 - e) a polynucleotide sequence complementary to a), b), c) or d).
- 24. (Reiterated) A method of detecting a target polynucleotide in a sample, said target polynucleotide having the sequence of a polynucleotide of claim 23, comprising

58830 3 09/397,558